Top-Rated StocksTop-RatedNASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $65.14 -1.25 (-1.88%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$75.01 +9.87 (+15.15%) As of 09:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$64.65▼$67.1750-Day Range$56.79▼$68.1152-Week Range$40.61▼$75.01Volume552,607 shsAverage Volume558,438 shsMarket Capitalization$4.14 billionP/E RatioN/ADividend YieldN/APrice Target$78.07Consensus RatingBuy Company Overview Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic and endocrine-related disorders of obesity. The company’s lead product, setmelanotide (IMCIVREE), is an FDA-approved melanocortin-4 receptor (MC4R) agonist designed to address the underlying genetic causes of obesity in patients with specific genetic deficiencies, including POMC, PCSK1 and LEPR deficiencies. Beyond its approved indications, Rhythm is actively pursuing additional clinical trials to expand the use of setmelanotide to other rare genetic obesity disorders and exploring its potential in common obesity populations. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals has established a robust pipeline aimed at transforming the treatment landscape for patients affected by rare obesity disorders. The company’s research and development efforts concentrate on the melanocortin pathway, which plays a central role in energy homeostasis and appetite regulation. Rhythm’s approach combines targeted molecular design with precision medicine, enabling tailored therapies that directly address specific genetic mutations. Its R&D infrastructure includes state-of-the-art laboratories and strategic collaborations with academic institutions and patient advocacy groups worldwide. Rhythm Pharmaceuticals serves a global patient community through a network of specialty pharmacies, healthcare providers and patient support programs. While its primary market is in the United States, the company is pursuing international regulatory approvals and partnerships to extend its reach into Europe and other key markets. Rhythm’s patient-centric initiatives include education, genetic testing support and financial assistance programs aimed at improving access to treatment for individuals with pathogenic genetic variants. Under the leadership of Chief Executive Officer David Meeker, Rhythm has grown its management team and board of directors with experienced professionals in biotechnology, regulatory affairs and commercial strategy. Meeker, previously a key executive at Amicus Therapeutics, brings extensive expertise in rare disease drug development and global commercialization. The company’s leadership team continues to expand as Rhythm advances its clinical programs and prepares for broader market launches.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 299th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 186.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.97% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.80 Percentage of Shares Shorted7.97% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.55 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rhythm Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest8 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,599,572.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Stock News HeadlinesInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 1,319 Shares of StockJuly 4, 2025 | insidertrades.comRhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity2 hours ago | globenewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.July 9 at 2:00 AM | Traders Agency (Ad)Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic ObesityJuly 8 at 4:01 PM | globenewswire.comRhythm of ResistanceJuly 8 at 3:36 PM | msn.comLeerink Partners Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform RecommendationJuly 8 at 10:36 AM | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Leerink PartnersJuly 8 at 3:51 AM | americanbankingnews.comRhythm Pharmaceuticals Inc News (RYTM) - Investing.comJuly 2, 2025 | investing.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $55.98 at the start of the year. Since then, RYTM shares have increased by 16.4% and is now trading at $65.14. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.12. Rhythm Pharmaceuticals's revenue was up 25.9% compared to the same quarter last year. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' top institutional shareholders include E. Ohman J or Asset Management AB (0.01%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, William T Roberts, Jennifer Kayden Lee, Jennifer Chien, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/07/2025Today7/09/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Price Target for Rhythm Pharmaceuticals$78.07 High Price Target$94.00 Low Price Target$63.00 Potential Upside/Downside+19.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$260.60 million Net Margins-123.26% Pretax Margin-123.19% Return on Equity-739.62% Return on Assets-44.27% Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.13 Sales & Book Value Annual Sales$130.13 million Price / Sales31.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book186.11Miscellaneous Outstanding Shares63,620,000Free Float59,740,000Market Cap$4.14 billion OptionableOptionable Beta2.26 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RYTM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.